340B Drug Pricing Program
The Centers for Medicare & Medicaid Services Nov. 1 released the calendar year 2020 outpatient prospective payment system/ambulatory surgical center payment system final rule.
The Centers for Medicare & Medicaid Services late today issued a final rule that increases Medicare hospital outpatient prospective payment system rates.
In an era of skyrocketing drug prices, the 340B drug pricing program is helping to ensure access to care for vulnerable patients and communities across the nation.
For more than 25 years, 340B has been critical in helping hospitals expand access to comprehensive health services, including…
To ensure good stewardship of the 340B program, hospitals participating in the program should structure hospital policies and practices to demonstrate their commitment. That demonstration of commitment includes sharing publicly how 340B savings are used to benefit the community, by, for example…
The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.
The Centers for Medicare & Medicaid Services yesterday proposed surveying hospitals about their acquisition costs for specified covered outpatient drugs under the 340B drug savings program.
In a letter to Representatives Peter Welch and David B. McKinley:The AHA expresses support for H.R. 4538, the Closing Loopholes for Orphan Drugs Act.
The AHA appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2020.